➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Boehringer Ingelheim
Express Scripts
Colorcon

Last Updated: June 21, 2021

DrugPatentWatch Database Preview

BASAGLAR Drug Profile


Email this page to a colleague

« Back to Dashboard

Recent Clinical Trials for BASAGLAR

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Eli Lilly and CompanyPhase 4
SanofiPhase 4
LMC Diabetes & Endocrinology Ltd.Phase 4

See all BASAGLAR clinical trials

Recent Litigation for BASAGLAR

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc.2018-05-31
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08
Purdue Pharmaceutical v. Actavis Elizabeth LLC2015-05-13

See all BASAGLAR litigation

Patent Text Search: US Patents for BASAGLAR

These patents were identified by searching patent claims

Supplementary Protection Certificates for BASAGLAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
26/2017 Austria   Get Started Free PRODUCT NAME: INSULIN GLARGIN UND LIXISENATID; REGISTRATION NO/DATE: EU/1/16/1157 (MITTEILUNG) 20170113
C20170015 00230 Estonia   Get Started Free PRODUCT NAME: GLARGIIN-INSULIIN/LIKSISENATIID;REG NO/DATE: EU/1/16/1157 13.01.2017
2017/022 Ireland   Get Started Free PRODUCT NAME: A COMPOSITION COMPRISING INSULIN GLARGINE, OR A PHARMACOLOGICALLY TOLERABLE SAFT THEREOF, AND LIXISENATIDE, OR A PHARMACOLOGICALLY TOLERABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/16/1157 20170111
C201730022 Spain   Get Started Free PRODUCT NAME: SULIQUA-INSULINA GLARGINA/ LIXISENATIDA; NATIONAL AUTHORISATION NUMBER: EU/1/16/1157; DATE OF AUTHORISATION: 20170111; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1157; DATE OF FIRST AUTHORISATION IN EEA: 20170111
PA2017020,C2498802 Lithuania   Get Started Free PRODUCT NAME: INSULINAS GLARGINAS + LIKSISENATIDAS; REGISTRATION NO/DATE: EU/1/16/1157 20170111
132017000077235 Italy   Get Started Free PRODUCT NAME: COMPOSIZIONE FARMACEUTICA COMPRENDENTE INSULINA GLARGINA E LIXISENATIDE(SULIQUA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1157, 20170113
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
McKesson
McKinsey
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.